


## DDO-5936

<b>Cat. No.:</b>	HY-139301		
<b>CAS No.:</b>	2355377-13-6		
<b>Molecular Formula:</b>	C <sub>25</sub> H <sub>29</sub> N <sub>5</sub> O <sub>4</sub> S		
<b>Molecular Weight:</b>	495.59		
<b>Target:</b>	HSP		
<b>Pathway:</b>	Cell Cycle/DNA Damage; Metabolic Enzyme/Protease		
<b>Storage:</b>	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



### SOLVENT & SOLUBILITY

<b>In Vitro</b>	DMSO : 12.5 mg/mL (25.22 mM; ultrasonic and warming and heat to 60°C)				
		Solvent Concentration	Mass 1 mg	5 mg	10 mg
	<b>Preparing Stock Solutions</b>	1 mM	2.0178 mL	10.0890 mL	20.1780 mL
		5 mM	0.4036 mL	2.0178 mL	4.0356 mL
10 mM		0.2018 mL	1.0089 mL	2.0178 mL	
Please refer to the solubility information to select the appropriate solvent.					
<b>In Vivo</b>	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 1.25 mg/mL (2.52 mM); Clear solution				

### BIOLOGICAL ACTIVITY

<b>Description</b>	DDO-5936 is a potent and specific Hsp90-Cdc37 PPI inhibitor. DDO-5936 can be used for the research of colorectal cancer <sup>[1]</sup> .
<b>IC<sub>50</sub> &amp; Target</b>	Hsp90-Cdc37 PPI <sup>[1]</sup>
<b>In Vitro</b>	DDO-5936 is a Hsp90-Cdc37 PPI inhibitor with potency and specificity through binding to a critical site on Hsp90 involving Glu47 <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.
<b>In Vivo</b>	DDO-5936 (0~80 mg/kg; p.o.) shows effect at the high dose group <sup>[1]</sup> . DDO-5936 is well tolerated for the absence of serious weight loss. DDO-5936 high dose groups show that tumor cells in the xenografts decreased significantly. DDO-5936 shows limited oral efficiency <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Mice <sup>[1]</sup>
Dosage:	0~80 mg/kg
Administration:	P.o.
Result:	Showed a moderate effect at the high dose group.

## REFERENCES

[1]. Wang L, et al. Discovery and Optimization of Small Molecules Targeting the Protein-Protein Interaction of Heat Shock Protein 90 (Hsp90) and Cell Division Cycle 37 as Orally Active Inhibitors for the Treatment of Colorectal Cancer. J Med Chem. 2020;63(3):1

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA